Sodium prasterone sulfateCAS# 1099-87-2 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1099-87-2 | SDF | Download SDF |
| PubChem ID | 23668320 | Appearance | Powder |
| Formula | C19H27NaO5S | M.Wt | 390.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | sodium;[(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] sulfate | ||
| SMILES | CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)OS(=O)(=O)[O-])C.[Na+] | ||
| Standard InChIKey | GFJWACFSUSFUOG-ZJTJBYBXSA-M | ||
| Standard InChI | InChI=1S/C19H28O5S.Na/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18;/h3,13-16H,4-11H2,1-2H3,(H,21,22,23);/q;+1/p-1/t13-,14-,15-,16-,18-,19-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Sodium prasterone sulfate Dilution Calculator
Sodium prasterone sulfate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.5608 mL | 12.8041 mL | 25.6082 mL | 51.2164 mL | 64.0205 mL |
| 5 mM | 0.5122 mL | 2.5608 mL | 5.1216 mL | 10.2433 mL | 12.8041 mL |
| 10 mM | 0.2561 mL | 1.2804 mL | 2.5608 mL | 5.1216 mL | 6.402 mL |
| 50 mM | 0.0512 mL | 0.2561 mL | 0.5122 mL | 1.0243 mL | 1.2804 mL |
| 100 mM | 0.0256 mL | 0.128 mL | 0.2561 mL | 0.5122 mL | 0.6402 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Granisetron
Catalog No.:BCC1601
CAS No.:109889-09-0
- CGS 9343B
Catalog No.:BCC7303
CAS No.:109826-27-9
- Kaempferol 5,7,4'-trimethyl ether
Catalog No.:BCN6587
CAS No.:1098-92-6
- Harmalidine
Catalog No.:BCN5889
CAS No.:109794-97-0
- ASP3026
Catalog No.:BCC1372
CAS No.:1097917-15-1
- 9R-10alpha-Hydroxyepigambogic acid
Catalog No.:BCN3079
CAS No.:1097882-33-1
- Homopahutoxin
Catalog No.:BCN1812
CAS No.:109777-68-6
- 8 beta-(4-Acetoxy-5-hydroxytigloyloxy)costunolide
Catalog No.:BCN7123
CAS No.:109770-86-7
- cis-Dehydroosthol
Catalog No.:BCN4735
CAS No.:109741-40-4
- Murraol
Catalog No.:BCN5888
CAS No.:109741-38-0
- MLN 2480
Catalog No.:BCC1771
CAS No.:1096708-71-2
- SPK-601
Catalog No.:BCC1961
CAS No.:1096687-52-3
- Kifunensine
Catalog No.:BCC7601
CAS No.:109944-15-2
- ITD 1
Catalog No.:BCC6409
CAS No.:1099644-42-4
- Succinic acid
Catalog No.:BCN5890
CAS No.:110-15-6
- Maleic acid
Catalog No.:BCN8426
CAS No.:110-16-7
- Fumaric acid
Catalog No.:BCN5989
CAS No.:110-17-8
- Sorbic acid
Catalog No.:BCN2218
CAS No.:110-44-1
- 8-O-Ethylyunaconitine
Catalog No.:BCN6260
CAS No.:110011-77-3
- Taurohyodeoxycholic Acid Sodium Salt
Catalog No.:BCC8363
CAS No.:110026-03-4
- Tussilagonone
Catalog No.:BCC8365
CAS No.:110042-38-1
- Calpain Inhibitor I, ALLN
Catalog No.:BCC1233
CAS No.:110044-82-1
- Strophantin K (mixture)
Catalog No.:BCC8256
CAS No.:11005-63-3
- 7-Hydroxy-3-(4-hydroxybenzylidene)chroman-4-one
Catalog No.:BCN1624
CAS No.:110064-50-1
Expression of anti-Mullerian hormone in two rat models of polycystic ovary syndrome.[Pubmed:27718294]
J Obstet Gynaecol Res. 2016 Dec;42(12):1761-1767.
AIM: Anti-Mullerian hormone (AMH) levels are two to three times higher in patients with polycystic ovary syndrome (PCOS), but the mechanism of increased AMH levels in PCOS remains unclear. The purpose of our experiment was to investigate a change in AMH levels in two kinds of commonly used rat models and to determine an ideal model for future research of AMH in the pathogenesis of PCOS. METHODS: Thirty female Sprague Dawley rats were treated using two modeling methods: implantation of a levonorgestrel silastic implant or injection with Sodium prasterone sulfate plus human chorionic gonadotropin (hCG). Rats in the control group were implanted with a blank silastic stick. Serum steroid concentrations, ovarian morphology and ovarian expression of AMH and AMH-receptor II (RII) proteins were determined and their correlations were studied. RESULTS: The results from the levonorgestrel and hCG group were closer to those displayed by human PCOS patients than the Sodium prasterone sulfate and hCG group. Ovarian local expression of AMH and AMH-RII was increased in these both models compared with the control group; however, an elevation of serum AMH concentration was not observed (12.53 +/- 0.99 ng/ml and 13.22 +/- 1.09 ng/ml vs 16.30 +/- 0.98 ng/ml). CONCLUSION: The levonorgestrel and hCG model is more suitable for the study of PCOS in puberty.
